NEOG Quote, Financials, Valuation and Earnings

Myriad Genetics, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of -13.32%. Neogen Corp.'s return on equity of -41.21% beat Myriad Genetics, Inc.'s return on equity of -69.09%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 14.38%. On the other hand Myriad Genetics, Inc. has an analysts' consensus of $8.52 which suggests that it could grow by 30.08%. Given that Myriad Genetics, Inc. has higher upside potential than Neogen Corp., analysts believe Myriad Genetics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Myriad Genetics, Inc. has a beta of 1.811, suggesting its more volatile than the S&P 500 by 81.148%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myriad Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Myriad Genetics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $209.2M, which are larger than Myriad Genetics, Inc. quarterly revenues of $205.7M. Neogen Corp.'s net income of $36.3M is higher than Myriad Genetics, Inc.'s net income of -$27.4M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Myriad Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.75x versus 0.73x for Myriad Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of -1338.77%. Neogen Corp.'s return on equity of -41.21% beat Outlook Therapeutics, Inc.'s return on equity of --.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 14.38%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $6.75 which suggests that it could grow by 268.85%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.174, suggesting its less volatile than the S&P 500 by 82.605%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $209.2M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of $1.5M. Neogen Corp.'s net income of $36.3M is higher than Outlook Therapeutics, Inc.'s net income of -$20.2M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.75x versus 35.25x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of 26.1%. Neogen Corp.'s return on equity of -41.21% beat ResMed, Inc.'s return on equity of 25.6%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 14.38%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.38%. Given that ResMed, Inc. has higher upside potential than Neogen Corp., analysts believe ResMed, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.60 per share. Neogen Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $209.2M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Neogen Corp.'s net income of $36.3M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while ResMed, Inc.'s PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.75x versus 6.84x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.